|
Erasca Inc (NASDAQ: ERAS) |
|
Erasca Inc
ERAS's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Erasca Inc 's sales fell
in the first quarter of 2025 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.43 %
Erasca Inc net loss decreased from $-35 millions, to $-31 millions in first quarter of 2025,
• More on ERAS's Growth
|
|
Erasca Inc realized a net loss in trailing twelve months.
Erasca Inc realized cash reduction of $ -0.02 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.32.
• More on ERAS's Valuation
|
|
|
|
|
Erasca Inc realized net loss in trailing twelve months.
Erasca Inc realized cash outflow of $ -0.02per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.32.
Erasca Inc Price to Book Ratio is at 0.99 lower than Industry Avg. of 34.08. and higher than S&P 500 Avg. of 0.01
• More on ERAS's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com